

VALUE & OUTCOMES SPOTLIGHT

SEPTEMBER/OCTOBER 2016 VOL. 2, NO. 5

LETTER FROM THE EDITOR

VALUE & OUTCOMES SPOTLIGHT EDITORS & EDITORIAL BOARD

EDITOR-IN-CHIEF – David Thompson, PhD, Real World Evidence Consulting, InVentivHealth, Burlington, MA, USA
David.Thompson@inventivhealth.com

CO-EDITORS – Murtuza Bharmal, PhD, Merck KGaA, Germany

EDITORIAL BOARD – Syed Mohamed Aljunid, PhD, United Nations University-International Institute For Global Health, Malaysia; Soraya Azmi, MBBS, MPH, Azmi Burhani Consulting, Malaysia; Amit Chhabra, MD, MPH, Pfizer, Inc., USA; Benjamin Craig, PhD, H. Lee Moffitt Cancer Center & Research Institute, USA; Yvonne Lee, MPH, Pfizer, Malaysia; Martin Marciniak, PhD, GlaxoSmithKline, USA; Axel C. Mühlbacher, PhD, MBA, HS Neubrandenburg, Germany; George Papadopoulos, BSc(Hons), Emerald Corporate Group Pty., Ltd., Australia; Stephen W. Schondelmeyer, PhD, University of Minnesota, USA; Gabriela Tannus, MSc, Axia.Bio, Brazil; Mondher Toumi, MD, PhD, MSc, University Aix-Marseille/Creativ-Ceutical, France; Gergana Zlateva, PhD, Pfizer, Inc., USA

MANAGEMENT ADVISORY BOARD – Nancy Devlin, PhD, OHE, UK; Josephine Mauskopf, PhD, RTI Health Solutions, USA; Gordon Liu, PhD

VALUE & OUTCOMES SPOTLIGHT PUBLISHING, SUBSCRIPTION, AND ADVERTISING OFFICE:

Value & Outcomes Spotlight
Print: ISSN 2375-866X
Online: ISSN 2375-8678
USPS: 019121

Published bi-monthly by:
ISPOR

505 Lawrence Square Blvd. South
Lawrenceville, NJ 08648 USA
Tel: 609-586-4981; Toll Free: 1-800-992-0643
Fax: 609-586-4982; Website: www.ispor.org

Periodicals Postage paid at Annapolis, MD 21401 and at additional mailing offices.

POSTMASTER: Send address changes to:
Value & Outcomes Spotlight
505 Lawrence Square Blvd., South
Lawrenceville, NJ 08648 USA

Managing Editor: Stephen L. Priori
email: spriori@ispor.org

Advertising Coordinator: Lyn Beamesderfer
email: lbeamesderfer@ispor.org

Direct photocopy permission and reprint requests to Managing Editor.

© 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). All rights reserved under International and Pan-American copyright conventions.

While *Value & Outcomes Spotlight* is designed to provide accurate information regarding the subject matters covered, the views, opinions, and recommendations expressed, are those of the contributors and not of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).



“It’s the season for value assessment frameworks” was the common refrain at a recently convened stakeholder conference organized by ISPOR as part of its Initiative on US Value Assessment Frameworks. No less than five such frameworks have been developed and are now being used with some regularity in the United States, including three different ones focusing specifically on oncology. Not surprisingly, the frameworks are similar in some respects but fundamentally different in others, geared towards different stakeholders, encompassing different dimensions of value, using different costing methodologies, and so on. But what’s important is that these frameworks are being put out there for public scrutiny and debate—because open and transparent health care decision making is certainly better than the alternative.

It’s interesting to note that value assessment frameworks are not new. Younger members of our Society may not realize that in its original formulation cost-effectiveness analysis was developed as a method of value assessment and budget-constrained resource allocation all in one—in other words, as a value assessment framework. If you read some of the earliest methods pieces published in the 1970s and ‘80s, you’ll find instruction on how to construct incremental cost-effectiveness ratios (ICERs) in much the same way we do today, but you’ll also find material on how to arrange the interventions in descending order of cost-effectiveness, and systematically allocate resources by going down the list selecting ones to adopt until an externally imposed budget constraint is reached. This approach guarantees obtaining the greatest health benefit from a fixed level of health care spending. At least in theory.

But in practice most of us have never used cost-effectiveness analysis in this way. The health care system is too complex, and numbers of interventions too vast, to ever be able to use the method for budget-constrained resource allocation. There was one notable quasi-attempt to do so, in the state of Oregon in the early 1990s, but this fell victim to methodological challenges and data limitations, and gave rise to a political firestorm that left cost-effectiveness analysis with a lasting stigma throughout the US of being a technocratic form of rationing, never to be trusted by patients in waiting rooms or voters at the ballot box.

Instead of using the constrained optimization part of cost-effectiveness analysis, the fall back approach initially was to assess the relative standing of a medical intervention by comparing its ICER to those of others (remember league tables?), judging it favorably if it was in the mix of currently accepted and reimbursed treatment modalities. The informality of this soon gave way to use of cost-effectiveness thresholds, which remain in place to this day even though they have generated their own share of controversy.

So the need for explicit and rigorous value assessment in the US has existed for a long time and ISPOR is doing something about it. A new Special Task Force has been convened and work is underway on a white paper to help sort through the five existing frameworks and make recommendations for a path forward. In addition to the one-day stakeholder engagement event, which drew more than 250 attendees, there will be an Issue Panel at the upcoming European Congress in Vienna devoted to potential learnings from European systems, and certainly more to come in 2017.

A developing story that *Value & Outcomes Spotlight* will be watching closely as it continues to unfold.

Sincerely,

David Thompson, PhD
Editor-in-Chief, *Value & Outcomes Spotlight*

Tell us what you think of the new *Value & Outcomes Spotlight*! Send feedback to vos@ispor.org or use the comments form at <http://www.ispor.org/ValueOutcomesSpotlight/CommentForm>